Literature DB >> 9474067

A study in contrasts: eligibility criteria in a twenty-year sample of NSABP and POG clinical trials. National Surgical Adjuvant Breast and Bowel Program. Pediatric Oncology Group.

A Fuks1, C Weijer, B Freedman, S Shapiro, M Skrutkowska, A Riaz.   

Abstract

We studied changes in eligibility criteria--the largest impediment to patient accrual--in two samples of clinical trials. Trials from the NSABP (National Surgical Adjuvant Breast and Bowel Program) and POG (Pediatric Oncology Group) were analyzed. After eliminating duplications, the criteria in each protocol were enumerated and classified according to a novel schema. NSABP trials contained significantly more criteria than POG trials, and added precision criteria (making study populations homogeneous) at a faster rate than POG studies. The difference between NSABP studies (explanatory trials) and POG studies (pragmatic trials) suggest that large numbers of eligibility criteria are not necessary for quality studies. We recommend that: (1) the inclusion/exclusion criteria distinction be abandoned; (2) eligibility criteria be explicitly justified; (3) the need for each criterion be assessed when new trials are planned; (4) criteria in phase III trials restricting patient accrual be minimized; and (5) further research be done to assess the impact of criteria on generalizability.

Entities:  

Mesh:

Year:  1998        PMID: 9474067     DOI: 10.1016/s0895-4356(97)00240-0

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  28 in total

Review 1.  Design issues for drug epidemiology.

Authors:  A D McMahon; T M MacDonald
Journal:  Br J Clin Pharmacol       Date:  2000-11       Impact factor: 4.335

2.  For and against: clinical equipoise and not the uncertainty principle is the moral underpinning of the randomised controlled trial.

Authors:  C Weijer; S H Shapiro; K Cranley Glass
Journal:  BMJ       Date:  2000-09-23

3.  Prior cancer does not adversely affect survival in locally advanced lung cancer: A national SEER-medicare analysis.

Authors:  Andrew L Laccetti; Sandi L Pruitt; Lei Xuan; Ethan A Halm; David E Gerber
Journal:  Lung Cancer       Date:  2016-05-31       Impact factor: 5.705

4.  Should criteria for inclusion in cancer clinical trials be expanded?

Authors:  David E Gerber; Sandi L Pruitt; Ethan A Halm
Journal:  J Comp Eff Res       Date:  2015-08       Impact factor: 1.744

5.  CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials.

Authors:  David Moher; Sally Hopewell; Kenneth F Schulz; Victor Montori; Peter C Gøtzsche; P J Devereaux; Diana Elbourne; Matthias Egger; Douglas G Altman
Journal:  BMJ       Date:  2010-03-23

6.  A distribution-based method for assessing the differences between clinical trial target populations and patient populations in electronic health records.

Authors:  C Weng; Y Li; P Ryan; Y Zhang; F Liu; J Gao; J T Bigger; G Hripcsak
Journal:  Appl Clin Inform       Date:  2014-05-07       Impact factor: 2.342

7.  A method for analyzing commonalities in clinical trial target populations.

Authors:  Zhe He; Simona Carini; Tianyong Hao; Ida Sim; Chunhua Weng
Journal:  AMIA Annu Symp Proc       Date:  2014-11-14

8.  The relationship between eligibility criteria and adverse events in randomized controlled trials of hematologic malignancies.

Authors:  A Statler; T Radivoyevitch; C Siebenaller; A T Gerds; M Kalaycio; E Kodish; S Mukherjee; C Cheng; M A Sekeres
Journal:  Leukemia       Date:  2016-12-07       Impact factor: 11.528

9.  Lessons for successful study enrollment from the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network Study.

Authors:  Susan T Crowley; Glenn M Chertow; Joseph Vitale; Theresa O'Connor; Jane Zhang; Roland M H Schein; Devasmita Choudhury; Kevin Finkel; Anitha Vijayan; Emil Paganini; Paul M Palevsky
Journal:  Clin J Am Soc Nephrol       Date:  2008-04-02       Impact factor: 8.237

10.  Consent timing and experience: modifiable factors that may influence interest in clinical research.

Authors:  David E Gerber; Drew W Rasco; Celette Sugg Skinner; Jonathan E Dowell; Jingsheng Yan; Jennifer R Sayne; Yang Xie
Journal:  J Oncol Pract       Date:  2011-12-06       Impact factor: 3.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.